Prostate Cancer Screening Binghamton NY

Prostate cancer screening consists of diagnostic tests that can assist with early detection of prostate cancer. Screening may involve a digital rectal exam, prostate-sspecific antigen (PSA) blood test, or a transrectal ultrasound. See below to learn more and to gain access to qualified oncologists in Binghamton, NY who provide prostate cancer screening.

Jonathan D Kloss
(607) 798-5307
169 Riverside Dr
Binghamton, NY
Kent B LaMoureux
(607) 798-5230
169 Riverside Dr
Binghamton, NY
Shing Chin
(607) 798-5230
169 Riverside Dr
Binghamton, NY
Arun V Sheth
(607) 798-5307
169 Riverside Dr
Binghamton, NY
Kent Butler Lamoureux, MD
607-798-5230
169 Riverside Dr
Binghamton, NY
Dr.Madhuri Yalamanchili
(607) 798-5307
169 Riverside Drive
Binghamton, NY
Adam Scott Levy, MD
607-772-1355
15 Bennett Ave
Binghamton, NY
Madhuri Yalamanchili, MD
607-748-3237
169 Riverside Dr
Binghamton, NY
Jonathan David Klos, MR
607-798-5818
169 Riverside Dr
Binghamton, NY
Joseph Andrew Readling, MD
607-763-6850
30 Harrison St Ste 100
Johnson City, NY
Data Provided by:
   

All about the PSA Test

The PSA (Prostate-Specific Antigen) test is one of two primary screening tools for prostate cancer. This simple blood test measures the level of PSA, a protein produced in the prostate, present in a man's body. Men typically have an initial PSA screening at 50, or earlier if there's a family history of prostate cancer.

Physicians measure PSA in nanograms per milliliter. An elevated PSA doesn't diagnose cancer and doesn't mean a man has prostate cancer; it just suggests further evaluation. Other medical conditions can also raise PSA levels. A PSA test and additional diagnostic tools help detect small tumors, however, experts say it does not necessarily reduce a man's chance of dying of prostate cancer.

An increase in PSA is the strongest single predictor of prostate cancer risk, and a high PSA score followed by a lower PSA score is not uncommon, even in men who do have cancer. However, PSA progression does predict poor overall survival rates in men with mestacized prostate cancer (meaning it has spread beyond the prostate). The PSA test is actually a better predictor of prostate cancer risk in African-American men with family histories compared to European- American men.

There is controversy over the value of PSA screenings. This spring, researchers released the results of a large-scale study that began in 1992 to evaluate whether or not the PSA test benefited men. In the subsequent media coverage of the results, the news varied widely depending on who was doing the reporting...

Click here to read more from Quality Health